Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
A Phase 1/2 Study of Alefacept, a CD2 Receptor Antagonist in Patients With Relapsed/Refractory Aplastic Anemia
Sponsor: Astellas Pharma US, Inc.
Terminated
Study drug not available at this time
Other terminated trials from Astellas Pharma US, Inc.
- Coronary Artery Disease · Phase NA · Jun 2021
- Angina · Phase EARLY_PHASE1 · Mar 2011
- Chest Pain · Phase NA · May 2010
- Hyponatremia · Phase PHASE4 · Feb 2010
- Overactive Bladder · Phase NA · Feb 2010
More terminations from Astellas Pharma US, Inc.
Listed as NCT01267643, this PHASE1 trial focuses on Aplastic Anemia and remains terminated or withdrawn. Sponsored by Astellas Pharma US, Inc., it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
▶ Show 2 earlier versions
-
Feb 2017 — Feb 2018 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma US, Inc.
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .